Zealand Pharma A/S
Investor News

Zealand Pharma to present at the J.P. Morgan 30th Annual Healthcare Conference

Copenhagen, 2012-01-04 14:49 CET (GLOBE NEWSWIRE) -- Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, will present at the 30th Annual J.P. Morgan Healthcare Conference taking place on 9 ? 12 January 2012 at the Westin St. Francis Hotel in San Francisco, California.

 The presentation will be led by David H. Solomon, President and Chief Executive Officer of Zealand Pharma and is scheduled for

Thursday, 12^th January 2012 at 9:00 PST (18:00 CET). 

Following presentation at the conference, a copy of the slide presentation will be available from the investor relations section of Zealand Pharma¡¯s website, www.zealandpharma.com.

For further information, please contact:

Hanne Leth Hillman, Vice President for IR & Corporate Communication,                         

Tel: +45 5060 3689, hlh@zealandpharma.com

About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing clinical pipeline of innovative peptide based drugs. The company's lead product is lixisenatide (Lyxumia? ¹⁾), a once-daily GLP-1 agonist for the treatment of Type 2 diabetes, invented by Zealand Pharma and licensed to Sanofi. In November, Sanofi filed for marketing authorization for lixisenatide (Lyxumia?) in Europe. Submission for regulatory approval of lixisenatide in the United States is expected in Q4 2012. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity, and a license agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the treatment of chemotherapy-induced diarrhea.

Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs, and all drug candidates in its pipeline have been identified through the company's own drug discovery activities. Zealand Pharma's products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com.

Note 1) Lyxumia? is the intended trademark for lixisenatide